25 February 2021BiotechnologyAlex Baldwin

Five minutes with… Irena Royzman

Since the formalisation of the new Biologics Price Competition and Innovation Act (BPCIA) framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

Five minutes with… Jacqueline Mulryne

26 November 2020 The partner at Arnold & Porter Kaye Scholer on second medical use patents, career goals after parenthood and the joy of being a “failed scientist” in IP.

Biotechnology

Five minutes with… Eva Kabir

2 March 2021 Since the formalisation of the new Biologics Price Competition and Innovation Act (BPCIA) framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.

Biotechnology

Five minutes with… Penny Gilbert

9 March 2021 The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.

More on this story

article

Five minutes with… Jacqueline Mulryne

26 November 2020 The partner at Arnold & Porter Kaye Scholer on second medical use patents, career goals after parenthood and the joy of being a “failed scientist” in IP.

Biotechnology

Five minutes with… Eva Kabir

Biotechnology

Five minutes with… Penny Gilbert

9 March 2021 The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.

More on this story

article

Five minutes with… Jacqueline Mulryne

26 November 2020 The partner at Arnold & Porter Kaye Scholer on second medical use patents, career goals after parenthood and the joy of being a “failed scientist” in IP.

Biotechnology

Five minutes with… Eva Kabir

Biotechnology

Five minutes with… Penny Gilbert

9 March 2021 The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.